The novel molecule 2‐[5‐(2‐chloroethyl)‐2‐acetoxy‐benzyl]‐4‐(2‐chloroethyl)‐phenyl acetate inhibits phosphoinositide 3‐kinase/Akt/mammalian target of rapamycin signalling through JNK activation in cancer cells

Abstract

Screening a compound library of compound 48/80 analogues, we identified 2‐[5‐(2‐chloroethyl)‐2‐acetoxy‐benzyl]‐4‐(2‐chloroethyl)‐phenyl acetate (E1) as a novel inhibitor of the phosphoinositide 3‐kinase/Akt pathway. In order to determine the mechanism of action of E1, we analysed the effect of E1 on components of the phosphoinositide 3‐kinase/Akt/mammalian target of rapamycin (mTOR) pathway. E1 demonstrated dose‐dependent and time‐dependent repression of Akt and mTOR activity in prostate and breast cancer cell lines, PC‐3 and MCF‐7, respectively. Inhibition of Akt and mTOR activity by E1 also coincided with increased c‐Jun NH2‐terminal kinase (JNK) phosphorylation. However, the mode of action of E1 is different from that of the mTOR inhibitor rapamycin. Proliferation and cell cycle analysis revealed that E1 induced cell cycle arrest and cell death in PC‐3 and MCF‐7 cells. Moreover, pretreatment of cancer cells with the JNK inhibitor SP600125 abolished the repression of Akt and mTOR activity by E1, indicating that the inhibition of Akt and mTOR by E1 is mediated through JNK activation. Consistently, E1 repressed Akt and mTOR activity in wild‐type and p38‐null mouse embryonic fibroblasts (MEFs), but not in MEFs lacking JNK1/2, and JNK‐null MEFs were less sensitive to the antiproliferative effects of E1. We further showed that E1 can function cooperatively with suboptimal concentrations of paclitaxel to induce cell death in PC‐3 and MCF‐7 cells. Taken together, these data suggest that E1 induces cancer cell death through the JNK‐dependent repression of Akt and mTOR activity and may provide a valuable compound for further development and research.

Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines

“…Furthermore, JNK1/2 activation Cell lysates were then prepared, and the expression of a JNK1/2 and pJNK1/2, b p38 and pp38, c AKT and pAKT, d GSK-3β and pGSK-3β, e β-catenin and f EGFR were examined using Western immunoblotting. Bars represent the mean ± SEM from 4 independent experiments Representative blots are shown above each bar graph repressed Akt activity in MCF-7 cells [52]. Recent studies have also suggested that a decrease in the level of Akt could lead to higher activity of p38 MAPK [53].…”

Menstrual cycle could affect Ki67 expression in estrogen receptor-positive breast cancer patients

“…Western blotting was performed on whole-cell extracts by lysing cells in SDS/PAGE buffer as previously described 17. Antibodies to Ki67 (MIB-1; Dako), ER (sc543; Santa Cruz Biotechnology, Dallas, Texas, USA), p21 (CP36, CP74; Millipore, Billerica, Massachusetts, USA) and α-tubulin (B-5-1-2; Sigma-Aldrich) were used at a dilution of 1:1000.…”

Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases

“…Western blotting was performed on whole-cell extracts by lysing cells in SDS/PAGE buffer as previously described ( Ho et al , 2009 ). Antibodies to FOXA1 (ab23738, Abcam), α -tubulin (B-5-1-2, Sigma-Aldrich, Tokyo, Japan), ER (sc543, Santa Cruz Biotechnology), PR (clone 16, Leica, Milton Keynes, UK), and CK5/6 (D5/16 B4, Dako) were used.…”